Decoy Therapeutics Stockholders Re-elect Directors, Approve Executive Pay and Auditor at 2026 Annual Meeting

Decoy Therapeutics Inc.

Quorum of 42.4% (225,548 of 531,968 shares) present at July 14, 2026 Annual Meeting.
Class II directors Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce re-elected with 23,204, 22,964, and 22,690 votes for, respectively.
Non-binding advisory vote on named executive officer compensation passed with 21,278 votes for, 5,041 against, and 1,007 abstentions.
Ratification of Ernst & Young LLP as independent auditor for FY2026 approved with 214,341 votes for, 9,584 against, 1,623 abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.